Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
1(11%)
Results Posted
125%(5 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_3
3
33%
Ph phase_2
3
33%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Terminated2
unknown1
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 23 (33.3%)
Phase 33 (33.3%)

Trials by Status

unknown111%
not_yet_recruiting111%
completed444%
active_not_recruiting111%
terminated222%

Recent Activity

1 active trials
Showing 5 of 9
terminatedphase_1

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT04902040
not_yet_recruitingphase_3

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

NCT07361484
completedphase_1

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

NCT03575793
active_not_recruitingphase_2

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

NCT05130827
completedphase_3

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

NCT03102606
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04902040Phase 1

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated
NCT07361484Phase 3

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Not Yet Recruiting
NCT03575793Phase 1

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Completed
NCT05130827Phase 2

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Active Not Recruiting
NCT03102606Phase 3

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Completed
NCT04345900Phase 2

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Completed
NCT03294577Phase 3

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Unknown
NCT04227990Phase 2

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Completed
NCT02846792Phase 1

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9